Abstract Purpose of Review Deep brain stimulation (DBS) is an established treatment in
several movement disorders, including Parkinson's disease, dystonia, tremor, and Tourette …

Acetylcholinesterase inhibitors (ChEI) are the global standard of care for the symptomatic
treatment of Alzheimer's disease (AD) and show significant positive effects in …

Neuroimaging studies suggest a pivotal role of amygdala dysfunction in non-motor
symptoms (NMS) of Parkinson's disease (PD). However, the relationship between amygdala …

Noradrenergic and cholinergic systems are among the most vulnerable brain systems in
neuropsychiatric diseases of ageing, including Alzheimer's disease, Parkinson's disease …

Abstract Development of neuroprotective therapeutics for Parkinson's disease (PD) is facing
a lack of translation from pre-clinical to clinical trials. One strategy for improvement is to …

Background Gait deficits in people with Parkinson's disease (PD) are triggered by
circumstances requiring gait adaptation. The effects of gait adaptation training on a split‐belt …

Cortical cholinergic deficits contribute to cognitive decline and other deficits in Parkinson's
disease. Cross-sectional imaging studies suggest a stereotyped pattern of posterior-to …

Mainstream transcriptome profiling of susceptibility versus resistance to age-related
diseases (ARDs) is focused on differentially expressed genes (DEGs) specific to gender …

Some patients with Parkinson disease (PD) present with mostly non-motor symptoms. Here,
Chaudhuri et al. discuss the evidence for CNS abnormalities in noradrenergic function in …

Diagnosis and clinical burden in people with Parkinson's disease (PD) is often related to the
cardinal motor features (tremor, bradykinesia, rigidity) and occurs when at least 40–60% of …